Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
- Fraser, Hannah
- Martin, Natasha K.
- Brummer-Korvenkontio, Henrikki
- Carrieri, Patrizia,
- Dalgard, Olav
- Dillon, John
- Goldberg, David
- Hutchinson, Sharon
- Jauffret-Roustide, Marie
- Kaberg, Martin
- Matser, Amy A.
- Maticic, Mojca
- Midgard, Havard
- Mravcik, Viktor
- Ovrehus, Anne
- Prins, Maria
- Reimer, Jens
- Robaeys, Geert
- Schulte, Bernd
- Santen, Daniela K.,
- Zimmermann, Ruth
- Vickerman, Peter
- Hickman, Matthew
DOIAbstract
International audienceBackground & aims: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10 years.Methods: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID.Results: At baseline, chronic HCV prevalence varied from 55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/No...
Add to ORKG